Roanoke-based cancer research startup, Acomhal Research Inc., secured a $399,878 Small Business Technology Transfer grant to determine if a molecule that stalls the spread of invasive brain cancer stem cells can help treat aggressive forms of breast cancer.
Good things come in small packages. Launched by Fralin Biomedical Research Institute’s Robert Gourdie, The Tiny Cargo Co. will package vital heart medicine in nano-containers extracted from cow’s milk.
With a focus on health sciences and technology, the HS&T Hokie Pitch will involve 30 students who have worked with real-world mentors, selected intellectual property, and created an entrepreneurial plan to develop and commercialize biomedical discoveries.
To explore potential sources of cellular electrical communication, the Fralin Biomedical Research Institute at VTC is hosting the world’s first Ephaptic Coupling Conference in Roanoke, Virginia, from May 5 to 7.
Teams will compete for $9,000 in prize money provided by the Virginia Tech Carilion Research Institute, Luna Innovations Inc., Carilion Clinic, the Apex Systems Center for Innovation and Entrepreneurship, and the Woods Rogers law firm.
Scientists at the Virginia Tech Carilion Research Institute have found evidence that may disrupt conventional understanding about how electrical activity travels in the heart — a discovery that potentially can lead to new insight into medical problems, such as heart arrhythmia and sudden cardiac death.
Deb Kelly, who is also an associate professor of biological sciences in the College of Science at Virginia Tech, is working to better detect, prevent, and repair the mutations found in cancers related to the breast cancer susceptibility protein, BRCA1.
The National Cancer Institute of the National Institutes of Health has awarded Deborah Kelly, an associate professor at the Virginia Tech Carilion Research Institute, $2 million to study the mutated form of the breast cancer susceptibility protein that is implicated in hereditary breast cancer.
Acomhal Research Inc., formed to fight a deadly type of brain cancer, is being recognized this week by the Association of Public and Land-Grant Universities and the Association of American Universities.
Research teams at the Virginia Tech Carilion Research Institute from three colleges — Engineering, Science, and Veterinary Medicine — are developing new approaches to treat glioblastoma, the aggressive form of brain cancer recently diagnosed in U.S. Sen. John McCain.
Sometimes it takes a researcher with a flair for entrepreneurship to translate a laboratory breakthrough into a medical treatment. Rob Gourdie, the director of the Virginia Tech Carilion Research Institute’s Center for Heart and Regenerative Medicine Research, uses "intrapreneurship" to translate laboratory breakthroughs into medical treatments.
Veeraragahavan studies the structural mechanisms underlying cardiac conduction in health and disease at the Virginia Tech Carilion Research Institute’s Center for Heart and Regenerative Medicine in the laboratory of center director, Rob Gourdie.
Steven Poelzing, an associate professor at the institute, will lead a research team to investigate how the microscopic spaces surrounding heart cells affect connections called gap junctions, which allow electrical impulses and small molecules to pass between cells.
The public is invited to learn more about heart development and current cardiovascular research during Virginia Tech Carilion Research Institute’s first heart school, held as part of American Heart Month.
At the Virginia Tech Carilion Research Institute, three scientists are planning to create a virus capable of destroying brain cancer. It sounds like the stuff of science fiction, but it isn’t hypothetical – the researchers were recently awarded a grant from the Commonwealth Research Commercialization Fund, part of the Center for Innovative Technology, to engineer a viral therapy.